Published in Exp Neurol on August 15, 2005
Mammalian nicotinic acetylcholine receptors: from structure to function. Physiol Rev (2009) 5.64
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Kynurenines in the mammalian brain: when physiology meets pathology. Nat Rev Neurosci (2012) 3.11
Kynurenines in the CNS: recent advances and new questions. Nat Rev Drug Discov (2012) 2.29
Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology (2010) 1.51
Increased levels of kynurenine and kynurenic acid in the CSF of patients with schizophrenia. Schizophr Bull (2010) 1.45
Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci (2009) 1.19
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol (2009) 1.18
Kynurenic acid leads, dopamine follows: a new case of volume transmission in the brain? J Neural Transm (Vienna) (2006) 1.12
Specific inhibition of kynurenate synthesis enhances extracellular dopamine levels in the rodent striatum. Neuroscience (2008) 1.07
The possible role of the kynurenine pathway in adolescent depression with melancholic features. J Child Psychol Psychiatry (2010) 1.05
The BTBR T+ tf/J mouse model for autism spectrum disorders-in search of biomarkers. Behav Brain Res (2012) 1.04
The kynurenine pathway as a therapeutic target in cognitive and neurodegenerative disorders. Br J Pharmacol (2013) 1.04
Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain. J Pharmacol Exp Ther (2011) 1.00
Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci Rep (2008) 0.99
The kynurenine pathway in adolescent depression: preliminary findings from a proton MR spectroscopy study. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.98
Neuroprotective effects of a novel kynurenic acid analogue in a transgenic mouse model of Huntington's disease. J Neural Transm (Vienna) (2010) 0.96
Structural basis of kynurenine 3-monooxygenase inhibition. Nature (2013) 0.94
Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain. J Neural Transm (Vienna) (2006) 0.92
Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies. J Neural Transm (Vienna) (2009) 0.92
Tryptophan, Neurodegeneration and HIV-Associated Neurocognitive Disorder. Int J Tryptophan Res (2010) 0.90
Neuroprotective kynurenine metabolite indices are abnormally reduced and positively associated with hippocampal and amygdalar volume in bipolar disorder. Psychoneuroendocrinology (2014) 0.86
Dopamine receptor activation reveals a novel, kynurenate-sensitive component of striatal N-methyl-D-aspartate neurotoxicity. Neuroscience (2007) 0.85
Subchronic elevation of brain kynurenic acid augments amphetamine-induced locomotor response in mice. J Neural Transm (Vienna) (2011) 0.84
Endogenous neuroprotection in chronic neurodegenerative disorders: with particular regard to the kynurenines. J Cell Mol Med (2011) 0.83
Forebrain striatal-specific expression of mutant huntingtin protein in vivo induces cell-autonomous age-dependent alterations in sensitivity to excitotoxicity and mitochondrial function. ASN Neuro (2011) 0.82
Glial metabolites of tryptophan and excitotoxicity: coming unglued. Exp Neurol (2005) 0.81
Alternative functions of the brain transsulfuration pathway represent an underappreciated aspect of brain redox biochemistry with significant potential for therapeutic engagement. Free Radic Biol Med (2014) 0.81
Elevated kynurenine pathway metabolism during neurodevelopment: Implications for brain and behavior. Neuropharmacology (2016) 0.79
Neuroprotective effects of probenecid in a transgenic animal model of Huntington's disease. J Neural Transm (Vienna) (2009) 0.78
Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice. Brain Res (2012) 0.76
Sustained elevation of kynurenic Acid in the cerebrospinal fluid of patients with herpes simplex virus type 1 encephalitis. Int J Tryptophan Res (2013) 0.75
Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases. Int J Mol Sci (2015) 0.75
High resolution crystal structures of human kynurenine aminotransferase-I bound to PLP cofactor, and in complex with aminooxyacetate. Protein Sci (2017) 0.75
Kynurenines and other novel therapeutic strategies in the treatment of dementia. Ther Adv Neurol Disord (2013) 0.75
Indoleamine 2,3 Dioxygenase as a Potential Therapeutic Target in Huntington's Disease. J Huntingtons Dis (2015) 0.75
Central Nervous System Infection with Borna Disease Virus Causes Kynurenine Pathway Dysregulation and Neurotoxic Quinolinic Acid Production. J Virol (2017) 0.75
TGR5-mediated bile acid sensing controls glucose homeostasis. Cell Metab (2009) 6.91
Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov (2008) 4.43
Kynurenine 3-monooxygenase inhibition in blood ameliorates neurodegeneration. Cell (2011) 3.28
Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med (2007) 3.15
Impaired spatial representation in CA1 after lesion of direct input from entorhinal cortex. Neuron (2008) 2.72
Family-wide chemical profiling and structural analysis of PARP and tankyrase inhibitors. Nat Biotechnol (2012) 2.58
Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities. J Pharmacol Exp Ther (2002) 2.37
Abnormal mitochondrial dynamics, mitochondrial loss and mutant huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet (2011) 2.34
Innocuous IFNgamma induced by adjuvant-free antigen restores normoglycemia in NOD mice through inhibition of IL-17 production. J Exp Med (2008) 2.28
A genomic screen in yeast implicates kynurenine 3-monooxygenase as a therapeutic target for Huntington disease. Nat Genet (2005) 2.28
Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells. Immunity (2002) 2.18
The kynurenine pathway modulates neurodegeneration in a Drosophila model of Huntington's disease. Curr Biol (2011) 2.17
TGR5 activation inhibits atherosclerosis by reducing macrophage inflammation and lipid loading. Cell Metab (2011) 2.17
Fishermen contribute to protection of marine reserves. Nature (2010) 1.96
The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology (2004) 1.96
Therapeutic potential of human umbilical cord mesenchymal stem cells in the treatment of rheumatoid arthritis. Arthritis Res Ther (2010) 1.90
Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem (2008) 1.85
6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem (2002) 1.85
The structure of Mediterranean rocky reef ecosystems across environmental and human gradients, and conservation implications. PLoS One (2012) 1.83
Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human melanoma. Cancer Immun (2009) 1.74
A genome-wide profiling of the humoral immune response to Chlamydia trachomatis infection reveals vaccine candidate antigens expressed in humans. J Immunol (2010) 1.55
Reduction of endogenous kynurenic acid formation enhances extracellular glutamate, hippocampal plasticity, and cognitive behavior. Neuropsychopharmacology (2010) 1.51
A sudden decline in active membrane-bound TGF-beta impairs both T regulatory cell function and protection against autoimmune diabetes. J Immunol (2004) 1.48
NK-cell activation by LIGHT triggers tumor-specific CD8+ T-cell immunity to reject established tumors. Blood (2005) 1.43
Remission of rheumatoid arthritis and potential determinants: a national multi-center cross-sectional survey. Clin Rheumatol (2014) 1.41
Structural basis for bile acid binding and activation of the nuclear receptor FXR. Mol Cell (2003) 1.40
Kynurenine pathway enzymes in dendritic cells initiate tolerogenesis in the absence of functional IDO. J Immunol (2006) 1.38
Methadone dosage and retention: an examination of the 60 mg/day threshold. J Addict Dis (2005) 1.38
Signaling via LTbetaR on the lamina propria stromal cells of the gut is required for IgA production. Nat Immunol (2002) 1.36
Neostriatal and cortical quinolinate levels are increased in early grade Huntington's disease. Neurobiol Dis (2004) 1.32
Nanomolar concentrations of kynurenic acid reduce extracellular dopamine levels in the striatum. J Neurochem (2005) 1.31
A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther (2005) 1.30
The astrocyte-derived alpha7 nicotinic receptor antagonist kynurenic acid controls extracellular glutamate levels in the prefrontal cortex. J Mol Neurosci (2009) 1.28
An unusual topological structure of the HIV-1 Rev response element. Cell (2013) 1.26
Solution structure of the cap-independent translational enhancer and ribosome-binding element in the 3' UTR of turnip crinkle virus. Proc Natl Acad Sci U S A (2010) 1.23
Early changes in Huntington's disease patient brains involve alterations in cytoskeletal and synaptic elements. J Neurocytol (2004) 1.23
Novel polymorphisms of nuclear receptor SHP associated with functional and structural changes. J Biol Chem (2010) 1.23
Targeted deletion of the kynurenine aminotransferase ii gene reveals a critical role of endogenous kynurenic acid in the regulation of synaptic transmission via alpha7 nicotinic receptors in the hippocampus. J Neurosci (2004) 1.23
Downregulated kynurenine 3-monooxygenase gene expression and enzyme activity in schizophrenia and genetic association with schizophrenia endophenotypes. Arch Gen Psychiatry (2011) 1.22
Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat. Neuropsychopharmacology (2003) 1.21
The farnesoid X receptor promotes adipocyte differentiation and regulates adipose cell function in vivo. Mol Pharmacol (2006) 1.20
PACSIN 1 interacts with huntingtin and is absent from synaptic varicosities in presymptomatic Huntington's disease brains. Hum Mol Genet (2002) 1.20
Astrocytic localization of kynurenine aminotransferase II in the rat brain visualized by immunocytochemistry. Glia (2007) 1.20
Impaired kynurenine pathway metabolism in the prefrontal cortex of individuals with schizophrenia. Schizophr Bull (2010) 1.19
Structure, expression, and function of kynurenine aminotransferases in human and rodent brains. Cell Mol Life Sci (2009) 1.19
Of mice, rats and men: Revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol (2009) 1.18
Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia. Schizophr Bull (2010) 1.18
RAP uses a histidine switch to regulate its interaction with LRP in the ER and Golgi. Mol Cell (2006) 1.18
A method for helical RNA global structure determination in solution using small-angle x-ray scattering and NMR measurements. J Mol Biol (2009) 1.16
Targeting kynurenine 3-monooxygenase (KMO): implications for therapy in Huntington's disease. CNS Neurol Disord Drug Targets (2010) 1.16
Protective effects of 6-ethyl chenodeoxycholic acid, a farnesoid X receptor ligand, in estrogen-induced cholestasis. J Pharmacol Exp Ther (2005) 1.16
Mitochondrial aspartate aminotransferase: a third kynurenate-producing enzyme in the mammalian brain. J Neurochem (2007) 1.15
Brief report: chimeric pigs produced from induced pluripotent stem cells demonstrate germline transmission and no evidence of tumor formation in young pigs. Stem Cells (2011) 1.12
On the relationship between the two branches of the kynurenine pathway in the rat brain in vivo. J Neurochem (2009) 1.11
Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther (2005) 1.11
Histone deacetylase inhibition modulates kynurenine pathway activation in yeast, microglia, and mice expressing a mutant huntingtin fragment. J Biol Chem (2007) 1.11
Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord (2005) 1.11
Biological pathway-based genome-wide association analysis identified the vasoactive intestinal peptide (VIP) pathway important for obesity. Obesity (Silver Spring) (2010) 1.10
Stimulating lymphotoxin beta receptor on the dendritic cells is critical for their homeostasis and expansion. J Immunol (2005) 1.10
Interleukin-15 and its receptor augment dendritic cell vaccination against the neu oncogene through the induction of antibodies partially independent of CD4 help. Cancer Res (2010) 1.07
Highlights at the gate of tryptophan catabolism: a review on the mechanisms of activation and regulation of indoleamine 2,3-dioxygenase (IDO), a novel target in cancer disease. Amino Acids (2008) 1.06
Acute elevations of brain kynurenic acid impair cognitive flexibility: normalization by the alpha7 positive modulator galantamine. Psychopharmacology (Berl) (2011) 1.06
3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease? Adv Exp Med Biol (2003) 1.05
PJA1, encoding a RING-H2 finger ubiquitin ligase, is a novel human X chromosome gene abundantly expressed in brain. Genomics (2002) 1.05
Pre- and postnatal exposure to kynurenine causes cognitive deficits in adulthood. Eur J Neurosci (2012) 1.04
Mutations of ANK3 identified by exome sequencing are associated with autism susceptibility. Hum Mutat (2012) 1.04
Novel isoquinolinone-derived inhibitors of poly(ADP-ribose) polymerase-1: pharmacological characterization and neuroprotective effects in an in vitro model of cerebral ischemia. J Pharmacol Exp Ther (2003) 1.04
Poly(ADP-ribose) catabolism triggers AMP-dependent mitochondrial energy failure. J Biol Chem (2009) 1.03
Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice. Neurobiol Dis (2006) 1.03
Biochemical and phenotypic abnormalities in kynurenine aminotransferase II-deficient mice. Mol Cell Biol (2004) 1.01
Molecular field analysis and 3D-quantitative structure-activity relationship study (MFA 3D-QSAR) unveil novel features of bile acid recognition at TGR5. J Chem Inf Model (2008) 1.01
Dispersal patterns of coastal fish: implications for designing networks of marine protected areas. PLoS One (2012) 1.01
Multidrug resistance in Klebsiella pneumoniae MGH78578 and cloning of genes responsible for the resistance. Biol Pharm Bull (2005) 1.01
A simple, high-throughput assay for Fragile X expanded alleles using triple repeat primed PCR and capillary electrophoresis. J Mol Diagn (2010) 1.01
Prognostic value of vascular endothelial growth factor expression in patients with esophageal cancer: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 1.00
Food groups and risk of esophageal cancer in Chaoshan region of China: a high-risk area of esophageal cancer. Cancer Invest (2003) 1.00
Improved identification of metabolites in complex mixtures using HSQC NMR spectroscopy. Anal Chim Acta (2008) 1.00
The methyl transferase PRMT1 functions as co-activator of farnesoid X receptor (FXR)/9-cis retinoid X receptor and regulates transcription of FXR responsive genes. Mol Pharmacol (2005) 1.00
Treatment of malignant biliary obstruction by combined percutaneous transhepatic biliary drainage with local tumor treatment. World J Gastroenterol (2006) 1.00
Age dependency of inhibition of alpha7 nicotinic receptors and tonically active N-methyl-D-aspartate receptors by endogenously produced kynurenic acid in the brain. J Pharmacol Exp Ther (2011) 1.00
The complementation of lymphotoxin deficiency with LIGHT, a newly discovered TNF family member, for the restoration of secondary lymphoid structure and function. Eur J Immunol (2002) 0.99
Substrate specificity and structure of human aminoadipate aminotransferase/kynurenine aminotransferase II. Biosci Rep (2008) 0.99
Investigation of surface endothelialization on biomedical nitinol (NiTi) alloy: Effects of surface micropatterning combined with plasma nanocoatings. Acta Biomater (2009) 0.99
Phase III trials of standard chemotherapy with or without bevacizumab for ovarian cancer: a meta-analysis. PLoS One (2013) 0.98